237 related articles for article (PubMed ID: 15037339)
21. The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.
Good KP; Rabinowitz J; Whitehorn D; Harvey PD; DeSmedt G; Kopala LC
Schizophr Res; 2004 May; 68(1):11-9. PubMed ID: 15037335
[TBL] [Abstract][Full Text] [Related]
22. Cognition in schizophrenia: impairments, determinants, and functional importance.
Bowie CR; Harvey PD
Psychiatr Clin North Am; 2005 Sep; 28(3):613-33, 626. PubMed ID: 16122570
[TBL] [Abstract][Full Text] [Related]
23. Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia.
Hill SK; Reilly JL; Harris MS; Khine T; Sweeney JA
Schizophr Bull; 2008 May; 34(3):494-506. PubMed ID: 17932088
[TBL] [Abstract][Full Text] [Related]
24. Facial recognition deficits and cognition in schizophrenia.
Sachs G; Steger-Wuchse D; Kryspin-Exner I; Gur RC; Katschnig H
Schizophr Res; 2004 May; 68(1):27-35. PubMed ID: 15037337
[TBL] [Abstract][Full Text] [Related]
25. Stability of attention deficits in schizophrenia.
Harris JG; Minassian A; Perry W
Schizophr Res; 2007 Mar; 91(1-3):107-11. PubMed ID: 17306962
[TBL] [Abstract][Full Text] [Related]
26. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia.
Gold S; Arndt S; Nopoulos P; O'Leary DS; Andreasen NC
Am J Psychiatry; 1999 Sep; 156(9):1342-8. PubMed ID: 10484943
[TBL] [Abstract][Full Text] [Related]
28. The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.
Selva-Vera G; Balanzá-Martínez V; Salazar-Fraile J; Sánchez-Moreno J; Martinez-Aran A; Correa P; Vieta E; Tabarés-Seisdedos R
BMC Psychiatry; 2010 Jun; 10():47. PubMed ID: 20550658
[TBL] [Abstract][Full Text] [Related]
29. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P
Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217
[TBL] [Abstract][Full Text] [Related]
30. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial.
Wykes T; Newton E; Landau S; Rice C; Thompson N; Frangou S
Schizophr Res; 2007 Aug; 94(1-3):221-30. PubMed ID: 17524620
[TBL] [Abstract][Full Text] [Related]
31. Neuropsychological functioning in schizophrenia patients with first-rank (passivity) symptoms.
Waters FA; Badcock JC; Dragović M; Jablensky A
Psychopathology; 2009; 42(1):47-58. PubMed ID: 19127100
[TBL] [Abstract][Full Text] [Related]
32. [Psychopathologic and cognitive investigations in schizophrenia].
Farkas M
Orv Hetil; 2009 Mar; 150(9):423-9. PubMed ID: 19228571
[TBL] [Abstract][Full Text] [Related]
33. Histories of childhood maltreatment in schizophrenia: relationships with premorbid functioning, symptomatology, and cognitive deficits.
Schenkel LS; Spaulding WD; DiLillo D; Silverstein SM
Schizophr Res; 2005 Jul; 76(2-3):273-86. PubMed ID: 15949659
[TBL] [Abstract][Full Text] [Related]
34. Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study.
Harvey PD; Palmer BW; Heaton RK; Mohamed S; Kennedy J; Brickman A
Am J Psychiatry; 2005 Jan; 162(1):110-7. PubMed ID: 15625208
[TBL] [Abstract][Full Text] [Related]
35. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients.
Mur M; Portella MJ; Martínez-Arán A; Pifarré J; Vieta E
J Clin Psychiatry; 2008 May; 69(5):712-9. PubMed ID: 18435565
[TBL] [Abstract][Full Text] [Related]
36. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
Davidson M; Galderisi S; Weiser M; Werbeloff N; Fleischhacker WW; Keefe RS; Boter H; Keet IP; Prelipceanu D; Rybakowski JK; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Kahn RS
Am J Psychiatry; 2009 Jun; 166(6):675-82. PubMed ID: 19369319
[TBL] [Abstract][Full Text] [Related]
37. Demographic, clinical, and neurocognitive predictors of quality of life in schizophrenia patients receiving conventional neuroleptics.
Sota TL; Heinrichs RW
Compr Psychiatry; 2004; 45(5):415-21. PubMed ID: 15332206
[TBL] [Abstract][Full Text] [Related]
38. Effects of D-cycloserine on negative symptoms in schizophrenia.
Duncan EJ; Szilagyi S; Schwartz MP; Bugarski-Kirola D; Kunzova A; Negi S; Stephanides M; Efferen TR; Angrist B; Peselow E; Corwin J; Gonzenbach S; Rotrosen JP
Schizophr Res; 2004 Dec; 71(2-3):239-48. PubMed ID: 15474895
[TBL] [Abstract][Full Text] [Related]
39. A six-factor model of cognition in schizophrenia and related psychotic disorders: relationships with clinical symptoms and functional capacity.
Gladsjo JA; McAdams LA; Palmer BW; Moore DJ; Jeste DV; Heaton RK
Schizophr Bull; 2004; 30(4):739-54. PubMed ID: 15957196
[TBL] [Abstract][Full Text] [Related]
40. Neurocognitive decline in early-onset schizophrenia compared with ADHD and normal controls: evidence from a 13-year follow-up study.
Øie M; Sundet K; Rund BR
Schizophr Bull; 2010 May; 36(3):557-65. PubMed ID: 18801881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
